Latest Safety News

Bowen Coking Coal reported a strong December quarter with record coal sales and a 39% reduction in cash costs, underpinning a $29 million EBITDA despite softer coal prices.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Kingfisher Mining has confirmed two new rare earth element lodes and reported exceptional copper assays, bolstering its position in the Gascoyne region amid ongoing strategic diversification.

AIC Mines delivered a robust December quarter with record copper production at Eloise and promising exploration results at Jericho, underpinning its growth strategy.

Stanmore Resources capped off 2024 with record saleable coal production of 13.8 million tonnes, exceeding guidance despite operational headwinds. Strong performances at South Walker Creek and Poitrel, alongside strategic financial moves and a pioneering renewable fuels trial, position the company well for 2025.

Merchant House International Limited reports the completion of its Tianjin asset sale and the cessation of AMI operations, signaling a strategic wind-up and delisting plan.

Advanced Braking Technology Ltd (ASX: ABV) reported a robust 24% increase in product sales revenue for Q2 FY25, driven by international expansion and the launch of its innovative BrakeiQ system. The company’s underlying profit also grew by 25%, underscoring operational efficiencies and a strong global pipeline.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Red Hawk Mining has made significant progress on its Blacksmith Iron Ore Project, submitting a mining proposal and reporting positive sinter test results, while managing tight cash reserves through asset sales and loan negotiations.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.